CRMP-3 Polyclonal Antibody

Background:
disease:Antibodies against post-translationally modified DPYSL4, also called anti-CV2 autoantibodies, are present in sera from patients with paraneoplastic neurological diseases (PND). PND are disorders of the nervous system associated with various systemic cancers which are not a direct result of the tumor mass or metastasis, but attributed to remote effects of the cancer.,function:Necessary for signaling by class 3 semaphorins and subsequent remodeling of the cytoskeleton. Plays a role in axon guidance, neuronal growth cone collapse and cell migration.,PTM:Phosphorylated upon DNA damage, probably by ATM or ATR.,similarity:Belongs to the DHOase family. Hydantoinase/dihydropyrimidinase subfamily.,subunit:Homotetramer, and heterotetramer with CRMP1, DPYSL2, DPYSL3 or DPYSL5. Interacts with PLEXA1.,

Alternative Names:
DPYSL4, CRMP3, ULIP4, Dihydropyrimidinase-related protein 4, DRP-4, Collapsin response mediator protein 3, CRMP-3, UNC33-like phosphoprotein 4, ULIP-4

Immunogen: The antiserum was produced against synthesized peptide derived from human DPYSL4. AA range:91-140

Isotype: Rabbit

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Concentration: 1 mg/ml

Observed band: 62

GeneID: DPYSL4

Storage: -20°C/1 year

NOTE: For Research Use Only